

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Provocholine 100 mg Powder for nebuliser solution.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 20 mL vial contains 100 mg methacholine chloride.

3. PHARMACEUTICAL FORM

Powder for nebuliser solution, for inhalation, non-sterile.
White or off-white deliquescent crystalline powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

This medicinal product is for diagnostic use only.

Provocholine is indicated in adults (aged 17 and over) to detect bronchial airway hyperreactivity, to assist in the diagnosis of asthma when the clinical history is suggestive of the condition but there is normal spirometry and the diagnosis remains uncertain after additional evaluation (see section 4.2, section 4.4 and section 5.1).

4.2 Posology and method of administration

Methacholine challenge, even if correctly performed, may occasionally induce severe bronchospasm. Methacholine challenge should therefore only be conducted in specialist respiratory centres with appropriate resuscitation facilities.

Posology

Adults (aged 17 and over):

Provocholine is intended for single use only. Once reconstituted, the prepared solutions should be used immediately. Provocholine is administered only in solution for inhalation.

Before starting a Provocholine challenge test, pulmonary function must be tested and confirmed to be within the normal range. The patient's baseline FEV₁ (Forced Expiratory Volume in 1 second)/ FVC (forced vital capacity) ratio (FEV₁/FVC ratio), without exposure to nebulised diluent or Provocholine, must be greater than 70%, considered normal baseline spirometry, for the challenge test to proceed.

At commencement of the test, baseline FEV₁ should be measured following exposure to nebulised diluent, without Provocholine. Baseline FEV₁ following exposure to nebulised diluent should be used to calculate

any subsequent decline in FEV₁ following exposure to increasing concentrations of Provocholine. The test should be terminated if there is a 20%, or greater, decline in FEV₁ from baseline.

Preparation and Administration Instructions (Please refer to the training material included on the product website www.provocholine.co.uk prior to preparation of solutions and administration):

Dilutions: (Note: Do not inhale the powder. Do not handle this product if you suffer from asthma or allergies). All dilutions must be made with sterile 0.9% sodium chloride solution for injection, using empty, sterile borosilicate Type I glass vials. After adding the sodium chloride solution, shake each vial until you obtain a clear solution.

Dilution sequence

Table 1: Preparation of serial dilutions using a single vial of Provocholine powder 100 mg for nebuliser solution (methacholine chloride USP):

| Take | Add sterile 0.9% Sodium Chloride | Obtained dilution |
|----------------------|----------------------------------|-------------------|
| 100 mg Provocholine® | 6.25 mL | 16 mg/mL (A) |
| 3 mL of dilution A | 3 mL | 8 mg/mL (B) |
| 3 mL of dilution B | 3 mL | 4 mg/mL (C) |
| 3 mL of dilution C | 3 mL | 2 mg/mL (D) |
| 3 mL of dilution D | 3 mL | 1 mg/mL (E) |
| 3 mL of dilution E | 3 mL | 0.5 mg/mL (F) |
| 3 mL of dilution F | 3 mL | 0.25 mg/mL (G) |
| 3 mL of dilution G | 3 mL | 0.125 mg/mL (H) |
| 3 mL of dilution H | 3 mL | 0.0625 mg/mL (I) |
| 3 mL of dilution I | 3 mL | 0.03125 mg/mL (J) |

Use a sterile Hydrophilic Polyvinylidene Fluoride (PVDF) bacterial-retentive filter of pore size 0.22 µm when transferring the solution from each vial (at least 2 ml) to the nebuliser.

Method of administration

The testing should only be conducted under specialist medical supervision by a doctor familiar with all aspects of the methacholine challenge test.

Tidal Breathing Method:

The following method is based on the use of the Hudson RCI® MicroMist® Small Volume Nebuliser which has been characterised for delivered dose and aerodynamic particle size distribution with respect to the fine particle (≤ 5 µm) fraction and mass median aerodynamic diameter.

With the Hudson RCI® MicroMist® Small Volume Nebuliser operated using dry compressed air to power the nebuliser and a pressure regulator set to 50 lb/in² (psi) with a flow controller set to a flow rate of 4.5 LPM and a nebulisation time of one (1) minute, the following characteristics were found:

- The delivered dose (of the respirable fraction) was determined to be 380 mcg methacholine chloride for the 16 mg/mL Provocholine® solution.
- The % of particles $\leq 5 \mu\text{m}$ (fine particle fraction) was determined to be 75.1% for the 16 mg/mL Provocholine® solution.
- The mass median aerodynamic diameter (MMAD) was $3.4 \mu\text{m}$ within the range of $1.0 - 3.6 \mu\text{m}^1$.

The ERS 2017 technical standard on bronchial challenge testing provides that other suitable nebulisers may be used as long as the delivered dose and particle size are characterised.

1. Using a 3 mL syringe and needle, draw up 2-3 mL of the diluent (sterile 0.9% Sodium Chloride) and place it in the nebuliser vial. Attach the nebuliser and necessary tubing to an appropriate compressed gas source.
2. At this time, the subject should be told that subsequent aerosols may produce mild cough, chest tightness or shortness of breath. Tell the subject that if these symptoms become uncomfortable, to remove the face mask or mouthpiece and to stop inhaling the aerosol immediately. Try to avoid suggesting that these symptoms will definitely develop, as suggestion alone can lower the FEV₁. Remember that perception of airway narrowing can vary considerably between subjects, making it advisable to watch and listen for other signs such as wheeze and an altered pattern of breathing. Instructions to cease inhaling the aerosol if symptoms become troublesome should be repeated before every dose.
3. Use the Hudson RCI® MicroMist® Small Volume Nebuliser and dry compressed air to power the nebuliser.
4. Keeping the nebuliser well away from the patient, set the pressure regulator to 50 lb/in² (psi) and set the flow controller to a flow rate of 4.5 LPM.
5. Instruct the patient to relax and breathe the aerosol quietly (tidal breathing) for 1 minute.
6. Place the face mask loosely over the nose and mouth (or the mouthpiece in the mouth). Start the stopwatch immediately. The nebuliser should be kept vertical. The patient should hold the nebuliser so as to avoid warming the solution, and subsequently altering the output.
7. After exactly one minute, remove the nebuliser from the patient's mouth, turn off the flow meter, and discard the solution.

Measure the FEV₁ 30 and 90 seconds after the end of the inhalation. These values may be left at ambient (spirometer) temperature pressure saturated (ATPS). To be able to undergo the methacholine challenge test, the patient must have a baseline FEV₁ $\geq 70\%$ of the predicted value.

8. The concentration of the first aerosol of Provocholine® for the methacholine challenge test is 0.03125 mg/mL. Subsequent doses are given at approximately 5-minute intervals in doubling concentrations (i.e. 0.0625, 0.125, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 and 16.0 mg/mL).

If the FEV₁ falls by 20% or more from the mean baseline FEV₁ (ATPS) or to less than 1.0 litre, no further inhalations are given. (A physician should be consulted if the FEV₁ falls below 1.5 litres.)

9. Repeat steps 1 through 8 with each increasing concentration of Provocholine until the FEV₁ has fallen by 20% or more from baseline, or the FEV₁ is 1.5 litres or less, or the highest concentration

¹American Thoracic Society - Guidelines for Methacholine and Exercise Challenge Testing-1999 Am J Respir Crit Care Med Vol 161 pp 309-329, 2000.

has been given. Do not give any further aerosols of Provocholine. Note the last and second last concentration of Provocholine® prior to discontinuing inhalations. The PC₂₀ may be extrapolated from the last two points of the dose response curve.

10. After the test is completed, administer an inhaled beta-agonist to the patient to expedite the return of the FEV₁ to within 90% of baseline and to relieve any discomfort. The majority of patients revert to normal pulmonary function within 5 minutes after administration of a bronchodilator or within 30 – 45 minutes without a bronchodilator.

Wait 10 minutes and measure the FEV₁ and Vital Capacity. Patients should not be allowed to leave the laboratory until their FEV₁ has returned to within 90% of baseline.

After the test, reusable nebulisers should be sterilized according to manufacturer’s recommendations. Disposable nebulisers should be discarded appropriately

Calculation and Interpretation of Results:

The provocative concentration causing a 20% fall in FEV₁ (PC₂₀) can be calculated as described below:

1. Calculation of PC₂₀

With the tidal breathing method, airway responsiveness may be expressed as that concentration of Provocholine provoking a fall in FEV₁ of 20% (PC₂₀). The percent fall in FEV₁ can be calculated using the mean baseline FEV₁, as shown below:

$$\% \text{ fall in FEV}_1 = \frac{\text{mean baseline FEV}_1 - \text{lowest FEV}_1 \text{ post-Provocholine}}{\text{mean baseline FEV}_1} \times 100$$

% fall in FEV₁ is then plotted against the rising concentration of Provocholine (log scale). The PC₂₀ is obtained by linear interpolation between the last two points, as shown in Figure 1.




Figure 1: Calculation of PC₂₀

Alternatively, the PC₂₀ may be calculated as follows:

$$PC_{20} = \text{antilog} \left[\log C_1 + \frac{[(\log C_2 - \log C_1)(20 - R_1)]}{(R_2 - R_1)} \right]$$

Where:

C₁ = second last concentration (<20% FEV₁ fall)

C_2 = last concentration (>20% FEV₁ fall)

R_1 = % fall FEV₁ after C_1

R_2 = % fall FEV₁ after C_2

2. Interpretation of Results

A methacholine challenge test can be considered positive if there is a reduction in FEV₁ of 20% or more from baseline at a Provocholine concentration of 8 mg/mL or lower (provocation concentration, PC₂₀ ≤ 8 mg/mL. A methacholine challenge test is considered negative if FEV₁ declines by less than 20% from baseline following exposure to Provocholine at 16 mg/mL (PC₂₀ ≥ 16 mg/mL) which excludes bronchial airway hyperreactivity.

4.3 Contraindications

Provocholine is contraindicated in the following cases:

- Hypersensitivity to the active substance or other parasympathomimetic agents.
- Clinically apparent asthma, wheezing or with abnormal baseline spirometry (FEV₁ / FVC ratio less than 70%).
- Patients treated with beta blockers, since the response to methacholine chloride can be emphasized or prolonged and the patient may not respond easily to the treatment used for the restoration of respiration and alleviation of symptoms.
- Repeated administration of Provocholine through inhalation of doses higher than the dose administered on the day of the diagnostic test.
- Bradycardia.
- Known aortic aneurysm.
- Heart attack or stroke in the last 3 months.
- Uncontrolled hypertension.
- Patients with myasthenia gravis undergoing treatment with cholinesterase inhibitors.
- Recent eye surgery
- Risk from elevated intracranial pressure (e.g. cerebral aneurysm)

4.4 Special warnings and precautions for use

The test should be performed in accordance to current clinical practice guidelines. Take full clinical respiratory history, before embarking on methacholine challenge, given the occurrence of false positive test results with methacholine in other respiratory conditions, such as after influenza, upper respiratory tract infections or immunisations, in very old patients or in patients with chronic pulmonary diseases (cystic fibrosis, sarcoidosis, tuberculosis, chronic obstructive pulmonary disease). Challenge testing can be positive in patients with allergic rhinitis without asthma, in smokers, or in patients exposed to aerial contaminants.

Provocholine is to be administered only by inhalation. Provocholine is a bronchoconstrictor agent for diagnostic purposes only and should not be used as a therapeutic agent.

When administered orally or by injection, methacholine chloride is associated with nausea and vomiting, substernal pain or pressure, hypertension, fainting and transient complete heart block.

The challenge testing for Provocholine must only be carried out under specialist medical supervision by a doctor familiar with all aspects of the methacholine inhalation challenge testing technique, all contraindications, warnings and precautions, and the management of respiratory failure. The doctor

responsible for the testing must be contactable while it is being carried out and available immediately if needed. If the doctor is carrying out the testing himself, another person must be available to assist him if needed. The patient must never be left unattended during the testing. Emergency equipment and medication must be available immediately to treat acute respiratory failure.

Administration of Provocholine to patients with epilepsy, cardiovascular disease accompanied by bradycardia, vagotonia, peptic ulcer, thyroid disease, urinary tract obstruction or other conditions that could be adversely affected by a cholinergic agent should only be carried out if the doctor deems that the risk/benefit ratio to be positive for the patient.

It is essential that the baseline spirometry is accurate. If the baseline spirometry is not performed or measured accurately, and the initial FEV₁ is underestimated, subsequent falls after inhaling Provocholine solutions may not be detected, resulting in too high dose and excessive bronchoconstriction.

As a result of the administration of Provocholine severe bronchoconstriction and a reduction in respiratory function may occur. Patients with airway hyperreactivity can experience bronchoconstriction with doses as low as 0.03125 mg/ml. If severe bronchoconstriction occurs, this must be immediately reversed by administration of a rapid-acting inhaled bronchodilator agent (beta-agonist), precautions for which must be taken when the inhalation challenge testing is performed in patients receiving beta blockers, since it is possible that bronchoconstriction may not be reversed easily.

Subjects who suffer from asthma are noticeably more sensitive to bronchoconstriction induced by methacholine than healthy subjects.

To ensure the safe and effective use of challenge testing with Provocholine, patients should be informed about the symptoms that may occur as a result of the testing and how to manage them. Laboratory staff with asthma or allergies should be particularly careful and take necessary measures when handling the material or if they are performing testing on patients, see section 6.6.

4.5 Interaction with other medicinal products and other forms of interaction

The concomitant treatment of Provocholine and beta blockers is contraindicated, see section 4.3. The following medications for the treatment of asthma inhibit the airways' response to Provocholine, whereby their treatment must be interrupted before the testing, due to the duration of their effect: beta agonists, anti-muscarinics and theophylline (see the table below for more information).

Table 2: Medications which may decrease airway hyperresponsiveness and withholding time

| Medications | <i>Min. time interval from the last dose to the challenge testing (hrs)</i> |
|--|--|
| Short-acting β -agonists in conventional inhaled doses (e.g. Albuterol 200 μ g) | 6 |
| Long-acting β -agonists (e.g. salmeterol) | 36 |
| Ultra-long-acting β -agonists (e.g. indacaterol, vilanterol, olodaterol) | 48 |
| Ipratropium (Atrovent 40 μg) | 12 |
| Long-acting anti-muscarinic agents | ≥ 168 |

4.6 *Fertility, pregnancy and lactation*

Pregnancy:

There have been no animal reproduction studies with methacholine chloride. It is not known whether methacholine chloride can cause harm to the foetus when administered to pregnant patients. An inadequate oxygen supply during pregnancy can be harmful to the child. Provocholine should not be used during pregnancy unless the benefits clearly outweigh the risks.

Breast-feeding:

It is unknown whether methacholine chloride is excreted in human milk.

Provocholine should not be used during breast-feeding unless the benefits clearly outweigh the risks.

Fertility:

It is not known whether methacholine chloride affects fertility.

4.7 *Effects on ability to drive and use machines*

Provocholine has no influence on the ability to drive and on the use of machines.

4.8 *Undesirable effects*

Adverse reactions associated with inhaled methacholine challenge tests are rare, and include incidences of headache, throat irritation, light-headedness and itching.

A positive reaction to methacholine challenge may produce symptoms of bronchospasm, such as chest tightness, cough or wheezing that may require reliever bronchodilators.

The adverse reactions are classified by System Organ Class and frequency defined as follows: Very Common ($\geq 1/10$); Common ($\geq 1/100$, $<1/10$); Uncommon ($\geq 1/1,000$, $<1/100$); Rare ($\geq 1/10,000$, $<1/1,000$); Very Rare ($<1/10,000$), not known (cannot be estimated from the available data). Undesirable effects were associated with 153 inhaled methacholine chloride challenge tests.

Nervous System Disorders

Rare: Headache, dizziness

Respiratory, thoracic and mediastinal disorders

Rare: Throat irritation

Not known: Bronchospasm, chest tightness, cough, wheezing

Skin and subcutaneous tissue disorders

Rare: Itching

Reporting of suspected adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9 Overdose

Provocholine is administered only by inhalation. When administered orally or by injection overdose of methacholine chloride can cause syncope, with cardiac arrest and loss of consciousness. Serious toxic reactions should be treated with 0.5 – 1 mg of atropine sulphate, administered IM or IV.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other diagnostic agents, ATC code: V04CX

Methacholine chloride is the β -methyl derivative of acetylcholine and differs from this principally in its long duration and selectivity of action. Bronchial smooth muscle contains significant parasympathomimetic (cholinergic) innervation.

The pharmacological basis for the challenge testing with methacholine chloride in solution is that subjects who suffer from asthma are noticeably more sensitive to induced bronchoconstriction than healthy subjects. Bronchoconstriction occurs when the vagus nerve is stimulated and acetylcholine is released from the nerve endings. Muscle constriction is essentially confined to the site of release, since acetylcholine is rapidly converted by acetylcholinesterase.

When there is chronic airflow limitation with an FEV₁/VC of <70%, the test can be abnormal due to other pathophysiological causes such as smoker's bronchitis, emphysema or cystic fibrosis.

Compared with acetylcholine, methacholine chloride is hydrolysed more slowly by acetylcholinesterase, being practically resistant to inactivation by nonspecific cholinesterase or pseudocholinesterase.

Methacholine challenge aims to detect bronchial airways hyperreactivity to assist in the diagnosis of asthma, when there is diagnostic uncertainty following normal spirometry, and there is either:

- Fractional exhaled nitric oxide (FeNO) level of 40 ppb or more and no variability in peak flow reading; or
- FeNO level of 39 ppb or less with variability in peak flow readings.

In 1,500 asthma patients and 500 non-asthma patients (both atopic and non-atopic), 90% of the asthmatic patients had a medium or highly positive response to methacholine chloride. Less than 5% of individuals with allergies or non-atopic control subjects demonstrated a highly positive response. 27% of patients with allergies had a negative response compared to 49% of control subjects. Patients with allergies and healthy patients had a similar incidence of positive responses. 30% of patients with allergies had a medium-positive response compared with 18% of healthy patients with a family history of asthma and 8% of control subjects with a healthy family history. Differences were observed with healthy subjects where there is no family history of asthma.

Amongst the asthmatic patients, the severity of the asthma determined the bronchial sensitivity of the subjects to the challenge testing with methacholine. The sensitivity varied from 100 to several thousand times compared with that of normal subjects. However, in ex-asthmatic subjects, the level of bronchoconstriction was also related to the severity of previous asthmatic symptoms. The average sensitivity of ex-asthmatic subjects was, approximately, one tenth compared to asthmatic subjects.

In population studies, the prevalence of hyperreactivity to methacholine chloride ranges from 8 to 15%. Whilst the sensitivity level of asthmatic subjects is similar to that of non-asthmatic subjects, asthmatic subjects respond to average lower doses. Less sensitive asthmatic subjects generally have moderate, more stable diseases. The interpretation is easier when the result is either essentially positive ($PC_{20} < 1\text{ mg/ml}$ or $PD_{20} < 10$ cumulative respiratory units), or clearly negative (minimum change in FEV_1 with the maximum released dose).

A study investigating whether prostaglandin synthesis produces methacholine tolerance, revealed that the attenuation of methacholine's effect with repeated testing is not due solely to prostaglandin synthesis and must involve, in part, other mechanisms, such as changes in methacholine deposition, agonist-receptor interactions, or post-receptor responses. In addition, prostaglandin inhibitors may increase baseline methacholine responsiveness in healthy non-asthmatic subjects (Haber and Beckett, 1992).

Using a maximal methacholine concentration of 16 mg/ml in a study that assessed methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma, had shown no serious adverse reactions developed by the participants in the study (Anderson et al., 2009).

5.2 Pharmacokinetic properties

The extent of systemic absorption of methacholine after inhalation in humans is unknown due to an absence of pharmacokinetic data. See section 5.1 for information on systemic cholinergic pharmacodynamic effects following inhalational administration of methacholine.

5.3 Preclinical safety data

The acute (24 hour) oral LD_{50} of methacholine chloride and related compounds is 1,100 mg/kg in mice and 750 mg/kg in rats.

Studies of inhaled administration of methacholine chloride for 7 days in monkeys (0.02, 0.08 and 0.4 mg/kg) led to expected dose-dependent bronchoconstriction. This was characterized by an increase in respiratory rate and a decrease in tidal volume after 30 seconds. These changes reached a peak at 2 minutes, followed by a rise in pulmonary resistance and a decrease in compliance. Pulmonary function returned to normal 20 – 25 minutes after exposure ended. Although a typical pulmonary response / recovery sequence was observed after 7 days of repeat dosing, distinct changes in airway resistance were recorded at the end of the study. These changes were not reversed quickly in the maximum equivalent standard dose group, which were observed for 9 weeks.

A bacterial *in vitro* genotoxicity (Ames) study showed no evidence of mutagenic potential. No long-term animal studies of the carcinogenic effect of methacholine chloride have been performed. In addition, no reproductive toxicity studies have been performed.

6. PHARMACEUTICAL PARTICULARS

6.1 *List of excipients*

None.

6.2 *Incompatibilities*

Not applicable.

6.3 *Shelf life*

- Unreconstituted vials (powder): 3 years.
- Reconstituted vials should be used immediately, discard any remainder.

6.4 *Special precautions for storage*

- Unreconstituted vials (powder): Do not store above 30 °C.
- Reconstituted vials should be used immediately, discard any remainder.
- Reconstituted solution should not be refrigerated or frozen.

6.5 *Nature and contents of container*

Provocholine is presented in 20 mL amber Type I borosilicate glass vials with flip-off caps, containing 100 mg of methacholine chloride, packed in a carton containing 6 vials.

6.6 *Special precautions for disposal and other handling*

Provocholine is a potent bronchoconstrictor. Do not inhale the powder. Do not handle this material if you have asthma or hay fever. A low resistance filter should be applied to an expiratory port of any dosing apparatus, as necessary, to prevent Provocholine aerosol from being released into the air of the room.

Provocholine is intended for single use only. Reconstituted vials should be used immediately. Any unused liquid should be disposed of safely. Reconstituted solution should not be refrigerated or frozen.

When using Provocholine, any unused solution should be discarded from the nebuliser after each concentration.

7. MARKETING AUTHORISATION HOLDER

ACIC EUROPE LIMITED
Leontiou, 163,
CLERIMOS BUILDING,
2nd floor 3022 Limassol,
Cyprus
Tel: 00357 25 578696
Fax: 00357 25 563980
E-mail: medinfo@aciceurope.eu

8. MARKETING AUTHORISATION NUMBER

PL 41697/0006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27/08/2020

10. DATE OF REVISION OF THE TEXT

21/04/2022